Indirect comparisons of efficacy of zanubrutinib versus orelabrutinib in patients with relapsed or refractory chronic lymphocytic leukemia/small lymphocytic lymphoma or relapsed or refractory mantle cell lymphoma

We conducted two indirect comparisons to estimate the efficacy of zanubrutinib versus orelabrutinib in Chinese patients with relapsed or refractory (R/R) chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) or R/R mantle cell lymphoma (MCL). An unanchored matching-adjusted indirect comp...

Descripción completa

Detalles Bibliográficos
Autores principales: Song, Yuqin, Zhou, Keshu, Yang, Shenmiao, Hu, Jianda, Zou, Dehui, Gao, Sujun, Pan, Ling, Wang, Tingyu, Yang, Haiyan, Zhang, Huilai, Zhou, Daobin, Ji, Jie, Xu, Wei, Feng, Ru, Jin, Jie, Lv, Fangfang, Huang, Haiwen, Fan, Xiaosi, Xu, Sheng, Zhu, Jun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer US 2023
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10447591/
https://www.ncbi.nlm.nih.gov/pubmed/37420136
http://dx.doi.org/10.1007/s10637-023-01376-1

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10447591/
https://www.ncbi.nlm.nih.gov/pubmed/37420136
http://dx.doi.org/10.1007/s10637-023-01376-1

Ejemplares similares